Lantern Pharma Inc.
LTRN
$3.59
-$0.03-0.83%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -30.39% | 9.15% | 8.85% | -29.98% | -32.40% |
| Total Depreciation and Amortization | 6.89% | 3.46% | 2.66% | -72.53% | 4,337.84% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 356.50% | -968.18% | -87.67% | 180.82% | -174.53% |
| Change in Net Operating Assets | 243.64% | -203.15% | -114.15% | 142.36% | 212.69% |
| Cash from Operations | 28.85% | -7.55% | -69.16% | 9.36% | 6.28% |
| Capital Expenditure | -3.33% | 30.23% | -95.45% | 56.86% | -6.25% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 404.87% | 445.50% | 64.30% | -312.02% | 10.49% |
| Cash from Investing | 406.73% | 436.62% | 63.66% | -317.10% | 10.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -- | -100.00% | 110.94% | -- |
| Foreign Exchange rate Adjustments | -514.81% | 43.36% | 215.31% | -104.17% | 60.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 87.86% | 9.43% | -50.33% | 1.49% | -7.12% |